Allergic lung inflammation induces pulmonary vascular hyperresponsiveness

European Respiratory Journal

Volumn 28, Issue 2, 2006, Pages 370-377

  Witzenrath, Martin ^a   Ahrens, B ^a   Kube, S M ^a   Hocke, A C ^a   Rosseau, S ^a   Hamelmann, E ^a   Suttorp, N ^a   Schutte H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

5 hydroxytryptamine; Allergic inflammation; Isolated mouse lung; Ovalbumin; Pulmonary hypertension; Serotonin

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANGIOTENSIN II; BISINDOLYLMALEIMIDE; ENDOTHELIN 1; KETANSERIN; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; OVALBUMIN; PHOSPHOLIPASE C; PROTEIN KINASE C; RHO KINASE; SEROTONIN; SEROTONIN 1B ANTAGONIST; SEROTONIN 2A ANTAGONIST; THROMBOXANE RECEPTOR STIMULATING AGENT; TRICYCLO[4.3.0.1]DECAN 9 YL XANTHOGENATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; INHALATION TEST; INTRACELLULAR FLUID; ISOLATED LUNG; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG PERFUSION; LUNG VENTILATION; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; SENSITIZATION; SIGNAL TRANSDUCTION;

ANIMALS; FEMALE; HUMANS; HYPERSENSITIVITY; HYPERTENSION, PULMONARY; LUNG; MICE; MICE, INBRED BALB C; PNEUMONIA; PULMONARY ARTERY; PULMONARY CIRCULATION; SIGNAL TRANSDUCTION; VASOCONSTRICTION;

EID: 33845499480     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00080105     Document Type: Article

References (53)

1. Saetta M, Di Stefano A, Rosina C, Thiene G, Fabbri LM. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am Rev Respir Dis 1991; 143: 138-143.
2. Hale KA, Niewoehner DE, Cosio MG. Morphologic changes in the muscular pulmonary arteries: relationship to cigarette smoking, airway disease, and emphysema. Am Rev Respir Dis 1980; 122: 273-278.
3. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 892-905.
4. Voelkel NF, Cool CD. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: Suppl. 46, 28s-32s.
5. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003; 22: 358-363.
6. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
7. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: Suppl. 12, 13S-24S.
8. Greiser E. Epidemiologic studies on the relation between use of appetite depressants and primary vascular pulmonary hypertension. Internist (Berl) 1973; 14: 437-442.
9. Mark EJ, Patalas ED, Chang HT, Evans RJ, Kessler SC. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med 1997; 337: 602-606.
10. Michelakis ED, Weir EK. Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci 2001; 321: 292-299.
11. Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morin D. Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992; 22: 307-325.
12. Pabst R, Tschernig T. Perivascular capillaries in the lung: an important but neglected vascular bed in immune reactions? J Allergy Clin Immunol 2002; 110: 209-214.
13. Henderson WR Jr, Tang LO, Chu SJ, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002; 165: 108-116.
14. Singh B, Shinagawa K, Taube C, Gelfand EW, Pabst R. Strain-specific differences in perivascular inflammation in lungs in two murine models of allergic airway inflammation. Clin Exp Immunol 2005; 141: 223-229.
15. Tormanen KR, Uller L, Persson CG, Erjefalt JS. Allergen Exposure of Mouse Airways Evokes Remodeling of both Bronchi and Large Pulmonary Vessels. Am J Respir Crit Care Med 2005; 171: 19-25.
16. Hamelmann E, Schwarze J, Takeda K, et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997; 156: 766-775.
17. Hamelmann E, Takeda K, Schwarze J, Vella AT, Irvin CG, Gelfand EW. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes. Am J Respir Cell Mol Biol 1999; 21: 480-489.
18. Hamelmann E, Oshiba A, Loader J, et al. Antiinterleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. Am J Respir Crit Care Med 1997; 155: 819-825.
19. von Bethmann AN, Brasch F, Nusing R, et al. Hyperventilation induces release of cytokines from perfused mouse lung. Am J Respir Crit Care Med 1998; 157: 263-272.
20. Seybold J, Thomas D, Witzenrath M, et al. Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 2005; 105: 3569-3576.
21. Held HD, Martin C, Uhlig S. Characterization of airway and vascular responses in murine lungs. Br J Pharmacol 1999; 126: 1191-1199.
22. Skingle M, Beattie DT, Scopes DI, et al. GR127935: a potent and selective 5-HT1D receptor antagonist. Behav Brain Res 1996; 73: 157-161.
23. Luberto C, Hannun YA. Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C? J Biol Chem 1998; 273: 14550-14559.
24. Hurwitz R, Ferlinz K, Sandhoff K. The tricyclic anti-depressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler 1994; 375: 447-450.
25. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NIH Publication No 02-3659. Bethesda, National Heart, Lung and Blood Institute and GINA Executive Committee, 2004.
26. Petitpretz P, Brenot F, Azarian R, et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89: 2722-2727.
27. Cool CD, Rai PR, Yeager ME, et al. Expression of human herpes virus 8 in primary pulmonary hypertension. N Engl J Med 2003; 349: 1113-1122.
28. Bethlem EP, Schettino GP, Carvalho CR. Pulmonary schistosomiasis. Curr Opin Pulm Med 1997; 3: 361-365.
29. Carreira PE. Pulmonary hypertension in autoimmune rheumatic diseases. Autoimmun Rev 2004; 3: 313-320.
30. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997; 28: 434-442.
31. Weitzenblum E, Apprill M, Oswald M, Chaouat A, Imbs JL. Pulmonary hemodynamics in patients with chronic obstructive pulmonary disease before and during an episode of peripheral edema. Chest 1994; 105: 1377-1382.
32. Fernandes DJ, Mitchell RW, Lakser O, Dowell M, Stewart AG, Solway J. Do inflammatory mediators influence the contribution of airway smooth muscle contraction to airway hyperresponsiveness in asthma? J Appl Physiol 2003; 95: 844-853.
33. Fajardo I, Svensson L, Bucht A, Pejler G. Increased levels of hypoxia-sensitive proteins in allergic airway inflammation. Am J Respir Crit Care Med 2004; 170: 477-484.
34. Keegan A, Morecroft I, Smillie D, Hicks MN, MacLean MR. Contribution of the 5-HT(1B) receptor to hypoxia-induced pulmonary hypertension: converging evidence using 5-HT(1B)-receptor knockout mice and the 5-HT(1B/1D)-receptor antagonist GR127935. Circ Res 2001; 89: 1231-1239.
35. Bonnet S, Belus A, Hyvelin JM, Roux E, Marthan R, Savineau JP. Effect of chronic hypoxia on agonist-induced tone and calcium signaling in rat pulmonary artery. Am J Physiol Lung Cell Mol Physiol 2001; 281: L193-L201.
36. Hamelmann E, Cieslewicz G, Schwarze J, et al. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med 1999; 160: 934-941.
37. Morecroft I, Heeley RP, Prentice HM, Kirk A, MacLean MR. 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol 1999; 128: 730-734.
38. Hood S, Birnie D, Hillis S. The haemodynamic effects of subcutaneous sumatriptan, a 5HT1-receptor agonist. Br J Clin Pharmacol 1997; 43: 327-328.
39. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I. 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 1996; 119: 917-930.
40. MacLean MR. Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action? Trends Pharmacol Sci 1999; 20: 490-495.
41. Held HD, Uhlig S. Basal lung mechanics and airway and pulmonary vascular responsiveness in different inbred mouse strains. J Appl Physiol 2000; 88: 2192-2198.
42. Cargill RI, Lipworth BJ. The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature. Br J Clin Pharmacol 1995; 40: 11-18.
43. Harnett KM, Biancani P. Calcium-dependent and calcium-independent contractions in smooth muscles. Am J Med 2003; 115: Suppl. 3A, 24S-30S.
44. Morgan KG, Leinweber BD. PKC-dependent signalling mechanisms in differentiated smooth muscle. Acta Physiol Scand 1998; 164: 495-505.
45. Gafni J, Munsch JA, Lam TH, et al. Xestospongins: potent membrane permeable blockers of the inositol 1,4,5-trisphosphate receptor. Neuron 1997; 19: 723-733.
46. Bergner A, Sanderson MJ. ATP stimulates Ca2+ oscillations and contraction in airway smooth muscle cells of mouse lung slices. Am J Physiol Lung Cell Mol Physiol 2002; 283: L1271-L1279.
47. 3)-receptor. Am J Respir Crit Care Med 2000; 161: A418.
48. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 1994; 372: 231-236.
49. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997; 389: 990-994.
50. Schaafsma D, Gosens R, Bos IS, Meurs H, Zaagsma J, Nelemans SA. Allergic sensitization enhances the contribution of Rho-kinase to airway smooth muscle contraction. Br J Pharmacol 2004; 143: 477-484.
51. Mukai Y, Shimokawa H, Matoba T, et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 2001; 15: 1062-1064.
52. Kandabashi T, Shimokawa H, Miyata K, et al. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation 2000; 101: 1319-1323.
53. Lechin F, van der DB, Orozco B, Lechin M, Lechin AE. Increased levels of free serotonin in plasma of symptomatic asthmatic patients. Ann Allergy Asthma Immunol 1996; 77: 245-253.